ValuentumAd

Official PayPal Seal













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Nov 14, 2017
How Have Our “Best Ideas” Performed During 2017?
The top-weighted ideas are getting the job done, while we avoided one of the biggest missteps in all of 2017. We’ve had better years, but 2017 was still a great one.
Nov 14, 2017
GE Takes the Plunge, Halves Dividend
There may have been little surprise across the market when GE halved its dividend in its investor update November 13, but shares are selling off after management issued weaker-than-expected EPS guidance for 2018.
Nov 11, 2017
4 Burning Questions About Gilead Sciences
Image Source: Gilead. We were pleased with the jump in shares of Gilead Sciences following its recent addition to the newsletter portfolios. The equity has given back some of those gains more recently as questions have resurfaced on the vitality of the enterprise. In this article, we work through the top 4 questions for readers to consider in evaluating Gilead Sciences.
Nov 10, 2017
Could Sally Beauty Become Amazon’s “Whole Foods” Foray into Beauty Supply?
Image Source: Sally Beauty.  “The Amazon Effect” on traditional retail is not a new development, but there are some pockets of retail that were believed to be impenetrable by the e-commerce giant. We’re beginning to see that such a notion may have been nothing short of wishful thinking.
Nov 10, 2017
Qualcomm Surges to Fair Value on Broadcom Offer
Shares of Qualcomm have faced meaningful pressure for the majority of 2017 as it deals with a legal battle with Apple, but the stock has rallied after Broadcom offered the firm a deal worth $70 per share in cash and stock.
Nov 7, 2017
Michael Kors’ Stock Surges; Market Overreacts to Hanesbrands' Results
Image shown: Shares of Michael Kors have been rocketing higher recently. The stock is rated 9 on the Valuentum Buying Index. The sole 9 rating on the Valuentum Buying Index has had a very nice couple of months recently. Meanwhile, Hanesbrands is feeling the wrath of considerable selling pressure, and we don't think it is justified.
Nov 7, 2017
Analysis of Spark Energy (SPKE) and Brighthouse Financial (BHF)
Let's talk about an extremely risky microcap energy equity and a unique potential value opportunity in the insurance industry, Brighthouse Financial, the spinoff of Metlife.
Nov 3, 2017
Dividend Increases/Decreases for the Week Ending November 3
Let's take a look at companies raising/lowering their dividends this week.
Nov 2, 2017
The Price of Good Investment Research?
Photo credit: Phlebotomy Tech; Thomas Haynie Skimping on research could cost you big when the you-know-what hits the fan. Research firms are reportedly charging as much as $5,000 per hour for one-on-one meetings with top analysts. Access to basic research is now being priced at $40,000 a year at some firms.
Oct 31, 2017
Novartis Gearing Up for Growth
 Image Source: Novartis. Dividend Growth Newsletter portfolio idea Novartis continues to grow its free cash flow stream while producing a string of products still in the infancy of their respective growth curves. The pharma/biotech realm remains bedeviled with patent issues that can disrupt cash flow generation once protection is lost, causing us to look for companies positioned for a fresh leg of growth. To that end, let’s take a look at Novartis’ pipeline, near-term potential, and how it relates to its dividend health.


The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.